Clinical Trials Logo

Clinical Trial Details — Status: Unknown status

Administrative data

NCT number NCT02161055
Other study ID # LYG-1401-WW
Secondary ID
Status Unknown status
Phase Phase 4
First received June 5, 2014
Last updated July 22, 2014
Start date June 2014
Est. completion date December 2016

Study information

Verified date July 2014
Source Lianyungang Oriental Hospital
Contact Wenxue Wang, M.D., Ph.D.
Phone +8615151268106
Email 731545804@qq.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

An increase in blood glucose is a common clinical symptom in patients following traumatic brain injury. Studies confirm that death after traumatic brain injury was not only associated with nerve injury, but also correlated with abnormal physiological and metabolic reactions. Hyperglycemia is a manifestation of physiological and metabolic disorders after traumatic brain injury. Traumatic brain injury induced hyperglycemia, and then aggravated secondary injury to the brain. Therefore, it is of important clinical significance to study the treatment of hyperglycemia after traumatic brain injury.


Description:

Hyperglycemia induced by traumatic brain injury is directly correlated with patient prognosis. Previous studies showed that if blood glucose could be controlled < 6.11 mmol/L, prognosis would be good and mortality would be decreased by approximately 50%. Moreover, the incidence of ICU-related complications, especially infection, was obviously reduced. A study concerning severe traumatic brain injury analyzed the recovery of patients at 18 days, 3 months and 1 year after trauma, and demonstrated that the prognosis of patients with blood glucose levels < 11.1 mmol/L within 24 hours of hospital admission was apparently better than those whose blood glucose levels were > 11.1 mmol/L. Hyperglycemia occurred after traumatic brain injury and was treated with intensive insulin therapy. Thus, blood glucose levels were controlled between 4.4 and 6.1 mmol/L, which noticeably shortened insulin use and decreased the incidence of multiple organ dysfunction and mortality of patients with traumatic brain injury.

It is well known that hyperglycemia will appear after traumatic brain injury. However, there are few clinical studies addressing continuous dynamic monitoring of blood glucose of traumatic brain injury patients and the relationship between changes in blood glucose and the degree of traumatic brain injury. Insulin therapy for reducing injury to secondary nerve cells after traumatic brain injury and for improving functional prognosis has also not been explored.

When blood glucose level is > 7.0 mmol/L as measured twice by rapid examination within 2 hours of hospital admission, patients with hyperglycemia after severe closed traumatic brain injury will be randomly divided into the intensive therapy group and nonintensive therapy group according to the random number table.

Patients in both groups will be treated using the protocol as follows.

1. Craniotomy for traumatic brain injury to mainly decompress and remove hematoma. Standard trauma craniotomy and incision of trachea will be performed.

2. During the operation, all patients will undergo ventricular puncture. Cerebrospinal fluid will be obtained for biochemical analysis and cell culture.

3. All patients will be closely monitored in the ICU of the Department of Neurosurgery.

4. Therapeutic protocols for severe traumatic brain injury will be used.

5. Glucocorticoid can cause disorders of glucose metabolism, so glucocorticoids can not be regularly applied in these two groups.

6. When glucose was injected into the vein, insulin was added at the proportion of 5:1 to eliminate glucose effects on blood glucose.

Blood glucose measurement: Capillary blood will be obtained from the tip of the ring finger to measure blood glucose. For a period, the blood should be collected from the same finger to make sure an accurate measurement occurs. When blood glucose of a patient undergoing transfusion was measured, blood should be collected from the tip of the finger of the limb without transfusion to ensure the accuracy of measurement.

Monitoring of target blood glucose: insulin dose will be selected in accordance with the Yale Insulin Infusion Protocol.

1. Insulin will be infused into the vein using a micropump at 0.1 μ/kg•h;

2. When blood glucose levels are > 20.0 mmol/L, insulin will be infused at 10.0 μ/h;

3. When blood glucose levels are between 17.1 and 20.0 mmol/L, insulin will be infused at 8.0 μ/h;

4. When blood glucose levels are between 14.1 and 17.0 mmol/L, insulin will be infused at 6.0 μ/h;

5. When blood glucose levels are between 11.5 and 14.0 mmol/L, insulin will be infused at 4.0 μ/h;

6. Within 12 and 24 hours, blood glucose levels will be maintained within the range of target blood glucose. During this period, blood glucose levels will be monitored once every 2 hours, and insulin dose will be adjusted in time.

7. If blood glucose levels are higher than the target value, insulin dose could be gradually increased by 1-2 μ/h;

8. When blood glucose levels reach the target value, insulin dose could be gradually diminished until terminated.


Recruitment information / eligibility

Status Unknown status
Enrollment 144
Est. completion date December 2016
Est. primary completion date June 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

- Severe closed traumatic brain injury diagnosed in the clinic;

- Severe closed traumatic brain injury verified by CT examinations;

- Patients who are in accordance with the indications of craniotomy for severe traumatic brain injury;

- Blood glucose levels > 7.0 mmol/L measured twice by rapid examination within 2 hours of hospital admission;

- Glasgow coma score between 3 and 8;

- At the age of 18 - 80 years old;

- Irrespective of gender.

Exclusion Criteria:

- At the age of < 18 years old or > 80 years old;

- Glasgow coma score > 8;

- Patients combined with multiple site damage;

- Hemodialysis-dependent patients combined with diabetic nephropathy;

- Patients with nervous system disease before traumatic brain injury;

- Patients with a history of diabetes before suffering from a traumatic brain injury.

Study Design


Intervention

Drug:
Insulin
Insulin dose was selected in accordance with the Yale Insulin Infusion Protocol. • Amount of insulin (u) = [fasting blood glucose (mmol/L) × 18-100] × 10 × body weight (kilogram) × 0.6 ÷ 1000 ÷ 2

Locations

Country Name City State
China Lianyungang Oriental Hospital Lianyungang Jiangsu
China The First People's Hospital of Lianyungang Lianyungang Jiangsu

Sponsors (2)

Lead Sponsor Collaborator
Lianyungang Oriental Hospital The First People's Hospital of Lianyungang

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Other Evaluation of severity of patient's condition Glasgow coma score will evaluate the severity of patient's condition, as will a recording sheet evaluating the patient's condition at hospital admission. Acute Physiology and Chronic Health Evaluation II will occur on each subsequent day in ICU. An expected time of 7 days
Other CT monitoring of morphological changes in the brain CT scans will monitor the morphological changes in the brain on hospital admission, preoperation, 1-3 days postoperation, 7 days postoperation, and 14 days postoperation. Until 14 days after surgery
Other Monitoring of changes in cerebrospinal fluid Cerebrospinal fluid will be obtained for biochemical analysis and cell culture. Cerebrospinal fluid will be collected during surgery, and obtained at 1 week after surgery by lumbar puncture. 1 week after surgery
Primary Monitoring of target blood glucose Within 1 week of hospitalization, rapid blood glucose levels will be recorded once every 2 hours in each group. Glycosylated serum protein levels will be measured once a week, for 4 consecutive weeks. This index reflects the mean blood glucose levels of 2 - 3 weeks. 4 weeks
Secondary Mortality Percentage of patients who die during hospitalization period, at 1 week after surgery, at 2 weeks after surgery, and at 3 months after injury. 6 months after surgery
Secondary Evaluation of activity of daily living At 2 weeks after hospital admission, Modified Rankin Scale and Glasgow outcome score will be applied.
During follow-up at 3 months after injury, Barthel index, Glasgow outcome score and Modified Rankin Scale will be employed.
During follow-up at 6 months after injury, Barthel index and Glasgow outcome score will be used.
2 weeks after hospital admission, 3 months and 6 months after injury
See also
  Status Clinical Trial Phase
Completed NCT01267448 - Outpatient Discharge Therapy With Saxagliptin+MetforminXR vs GlipizideXL for Type 2 Diabetes With Severe Hyperglycemia Phase 4
Recruiting NCT03775733 - Efficacy and Safety of Hydrolysed Red Ginseng Extract on Improvement of Hyperglycemia N/A
Completed NCT03482154 - Malglycemia in the Pediatric Hematopoietic Stem Cell Transplant Population
Active, not recruiting NCT05477368 - Examining the Feasibility of Prolonged Ketone Supplement Drink Consumption in Adults With Type 2 Diabetes N/A
Completed NCT03675360 - Low-Carbohydrate Dietary Pattern on Glycemic Outcomes Trial N/A
Completed NCT00535600 - Effects of Bariatric Surgery on Insulin
Not yet recruiting NCT06159543 - The Effects of Fresh Mango Consumption on Cardiometabolic Outcomes in Free-living Individuals With Prediabetes N/A
Recruiting NCT02885922 - The Effects of add-on Anti-diabetic Drugs in Type 2 Diabetic Patients
Recruiting NCT02885909 - Inpatient Blood Glucose Control in Taichung Veterans General Hospital Phase 4
Withdrawn NCT01488383 - Effect of Stevioside in Postpandrial Glucose in Healthy Adults N/A
Completed NCT02012465 - Validation of Insulin Protocol for Glucocorticoid-induced Hyperglycemia in Diabetic Oncology Patients Early Phase 1
Completed NCT01805414 - Breakfast Nutrition and Inpatient Glycemia N/A
Completed NCT01803568 - Skeletal Muscles, Myokines and Glucose Metabolism MYOGLU N/A
Completed NCT01810952 - The Management of Glucocorticoid-Induced Hyperglycemia in Hospitalized Patients Phase 4
Active, not recruiting NCT01247714 - Clinical Evaluation of a Specific Enteral Diet for Diabetics N/A
Not yet recruiting NCT00846144 - The Reduction in Glucose Stimulated Insulin Secretion Induced by Cytokines May be Prevented by Copper Addition - Studies in Diabetic Patients N/A
Completed NCT00996099 - Continuous Glucose Monitoring Combined With Computer Algorithm for Intensive Insulin Therapy in Cardiosurgical Patients N/A
Recruiting NCT00654797 - Improving Blood Glucose Control With a Computerized Decision Support Tool: Phase 2 Phase 2
Completed NCT00468494 - Can Blood Glucose Levels During the Perioperative Period Identify a Population at Risk for Hyperglycemia? N/A
Completed NCT00394407 - Basal/Bolus Versus Sliding Scale Insulin In Hospitalized Patients With Type 2 Diabetes Phase 4